Drug Industry Bans Most Promotional Products
Slagle, on behalf of the PPAI board of directors, will continue to reach out to Billy Tauzin, president and CEO of PhRMA, to voice the industry’s opposition to this proposed code. PPAI will work with PhRMA to offer guidance on the effective and beneficial uses of promotional products in the health-care field, not only in the areas of direct patient care, but in cause marketing and awareness campaigns, where promotional products have a proven benefit, including cancer, heart disease, drug abuse awareness and prevention, and many others. “This is simply PhRMA responding to policymakers, health-care professionals and others telling them that they can do better—and we agree—they can and should do better. This is not the solution. Rather, the PhRMA industry must take a closer look at some of the overly aggressive business tactics utilized by many of its practitioners,” said Stan Breckenridge, MAS, PPAI chairman of the board. “This new code, and its Draconian reporting practices modeled after Sarbanes-Oxley compliance mechanisms, are sure to drive up administrative costs on the part of the pharmaceutical giants, and I fully expect these costs to be passed on to the patient.”
PPAI said it will continue to monitor these developments and attempt to work with PhRMA to reach a solution that will allow health-care professionals to receive medically relevant logoed items and business supplies in a reasonable manner that supports effective patient care.
For more information on PPAI, visit www.ppa.org